Administration of human recombinant insulin-like growth factor-I in critically ill patients

Critical Care Medicine

Volumn 25, Issue 8, 1997, Pages 1352-1361

  Yarwood, Gary D ^a   Ross, Richard J M ^b   Medbak, Sami ^a   Coakley, John ^a   Hinds, Charles J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Anabolic therapy; Catabolism; Critical illness; Growth hormone; Insulin like growth factor binding proteins 1 and 3; Insulin like growth factor I; Patient variability; Safety; Systemic inflammatory response syndrome

Indexed keywords

GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; FEMALE; HUMAN; HYPERMETABOLISM; INFLAMMATION; INTENSIVE CARE UNIT; MALE; MULTIPLE TRAUMA; PRIORITY JOURNAL; SEPSIS; STARVATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; CRITICAL ILLNESS; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0030849740     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199708000-00023     Document Type: Article

References (40)

1. Ross RJM, Miell J, Buchanan CR: Avoiding autocannibalism. BMJ 1991; 303:1147-1148
2. Ross RJM, Miell JP, Freeman E, et al: Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-1. Clin Endocrinol 1991; 35:47-51
3. Ross RJM, Miell JP, Holly JMP, et al: Levels of GH binding activity in IGFBP-1, insulin, blood glucose and cortisol in intensive care patients. Clin Endocrinol 1991; 35:361-367
4. Ho KY, Velduis JD, Johnson ML, et al: Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 1988; 81:968-975
5. Woolf PD: Hormonal responses to trauma. Crit Care Med 1992; 20: 216-226
6. Chwals WJ, Bistrian BR: Role of exogenous growth hormone and insulin-like growth factor I in malnutrition and acute metabolic stress: A hypothesis. Crit Care Med 1991; 19:1317-1322
7. Voerman BJ, Strack van Schijndel RJ, Groeneveld AB, et al: Effects of human growth hormone in critically ill nonseptic patients: Results from a prospective, randomized, placebo-controlled trial. Crit Care Med 1995; 23: 665-673
8. Wilmore DW: Catabolic illness: Strategies for enhancing recovery. N Engl J Med 1991; 325:695-702
9. Manson JM, Smith RJ, Wilmore DW: Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition. Ann Surg 1988; 208:136-142
10. Douglas RG, Humberstone DA, Haystead A, et al: Metabolic effects of recombinant human growth hormone: Isotopic studies in the postabsorptive state and during total parenteral nutrition. Br J Surg 1990; 77:785-790
11. Dahn MS, Lange MP, Jacobs LA: Insulin-like growth factor-I production is inhibited in human sepsis. Arch Surg 1988; 123:1409-1414
12. Gatzen C, Scheltinga MR, Kionbrough TD, et al: Growth hormone attenuates the abdominal distribution of body water in critically ill surgical patients. Ann Surg 1992; 112:181-187
13. Voerman HJ, van Schijndel RJMS, Groeneveld ABJ, et al: Effects of recombinant human growth hormone in patients with severe sepsis. Ann Surg 1992; 216:648-655
14. Gottardis M, Benzer A, Koller W, et al: Improvement of septic syndrome after administration of recombinant human growth hormone (rhGH). J Trauma 1991; 31:81-86
15. Jacob R, Barret E, Plewe G, et al: Acute effects of insulin-like growth factor-1 on glucose and amino acid metabolism in the awake fasted rat. J Clin Invest 1989; 83:1717-1723
16. O'Sullivan U, Gluckman PD, Breir BH, et al: Insulin-like growth factor-1 in mice reduces weight loss during starvation. Endocrinology 1989; 125: 2793-2794
17. Strock LL, Singh H, Abdullah A, et al: The effect of insulin-like growth factor-1 on post burn hypermetabolism. Surgery 1990; 108:161-164
18. Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor-1 in healthy adults. N Engl J Med 1987; 317:137-140
19. Laron Z, Klinger B, Jensen LT, et al: Biochemical and hormonal changes induced by one week of administration of rhIGF-1 to patients with Laron type dwarfism. Clin Endocrinol 1991; 35:145-150
20. Takano K, Hizuka N, Shizume K, et al: Repeated s.c. administration of recombinant human insulin-like growth factor-1 (IGF-1) to human subjects for seven days. Growth Regul 1991; 1:23-28
21. Clemmons DR, Smith-Banks A, Underwood LE: Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-1 in humans. J Clin Endocrlnol Metab 1992; 75:234-238
22. Berelowitz M, Szabo M, Frohman LA, et al: Somatomedin C mediates GH negative feedback by effects on both the hypothalamus and pituitary. Science 1981; 212:1279-1281
23. Ceda GP, Davis RG, Rosenfeld RG, et al: The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: Evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology 1987; 120:1658-1662
24. Miell JP, Taylor AM, Jones J, et al: Administration of human recombinant insulin-like growth factor-1 to patients following major gastrointestinal surgery. Clin Endocrinol 1992; 37: 542-551
25. Ross RJM, Miell JP, Holly JMP, et al: Levels of GH and IGF binding proteins, insulin, blood glucose and cortisol in intensive care patients. Clin Endocrinol 1991; 35:361-368
26. Holly JMP, Biddlecombe RA, Danger DB, et al: Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin: A new role for insulin? Clin Endocrinol 1988; 29:667-675
27. Suikkan AM, Koivisto VA, Rutanen EM: Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988; 66:266-272
28. Burch WM, Correa J, Shively JE, et al: The 25 kilodalton insulin-like growth factor (IGF) binding protein inhibits both basal and IGF-I mediated growth of chick embryo pelvic cartilage in vitro. J Clin Endocrinol Metab 1990; 70: 173-178
29. Taylor AM, Danger DB, Preece MA, et al: The growth hormone independent insulin-like growth factor-I binding protein BP-28 is associated with serum insulin-like growth factor-I inhibiting bioactivity in adolescent insulin-dependent diabetics. Clin Endocrinol 1990; 32:229-239
30. Zapf J, Hain C, Waldvogel M, et al: Recombinant human insulin-like growth factor-I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc Natl Acad Sci U S A 1989; 86:3813-3817
31. Timmins AC, Cotterill AM, Cwyfan Hughes SC, et al: Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med 1996; 24:1460-1466
32. Wilton P, Sietniks A, Gunnarson R, et al: Pharmacokinetic profile of recombinant human insulin-like growth factor given subcutaneously in normal subjects. Acta Paediatr Scand 1991; 377(Suppl):111-114
33. Laron Z, Klinger B, Erster B, et al: Effect of administration of insulin-like growth factor-I in patients with Laron-type dwarfism. Lancet 1988; i:1170-1172
34. Guler HP, Schmid C, Zapf J, et al: Effects of recombinant human insulin like growth factor-1 on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A 1989; 86:2868-2872
35. Froesch ER, Guler HP, Schmid C, et al: Therapeutic potential of insulin-like growth factor-I. Trends in Endocrinology Metabolism 1990; 1:254-260
36. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
37. Doughaday WH, Mariz IK, Blithen SL: Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: A comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid ethanol-extracted serum. J Clin Endocrinol Metab 1980; 51:781-788
38. Blum W: Insulin-like growth factors and their binding proteins. In: Functional Endocrinologic Diagnostics in Children and Adolescents. Ranke MB (Ed). Mannheim, J and J Verlag, 1992, pp 108-109
39. Hall K, Lundin G, Povoa G: Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa. Acta Endocrinol 1988; 118:321-326
40. Young SCJ, Underwood LE, Celniker A, et al: Effects of recombinant insulin like growth factor-I (IGF-I) and growth hormone on serum IGF-binding proteins in calorically restricted adults. J Clin Endocrinol Metab 1992; 75: 603-608